PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35456016-2	2022	In recent years, ibrutinib, an oral BTK inhibitor, became a breakthrough therapy for hematological malignancies, such as chronic lymphocytic.	ibrutinib	17-26	Bruton tyrosine kinase	Homo sapiens	36-39	
35456016-6	2022	Consequently, ibrutinib, a BTK-inhibitor, has been studied as a therapeutic option in solid malignancies.	ibrutinib	14-23	Bruton tyrosine kinase	Homo sapiens	27-30	
35456016-8	2022	Nevertheless, while ibrutinib failed as a monotherapy, it might become an interesting part of a multidrug regime: not only has a synergism between ibrutinib and other compounds, such as trametinib or dactolisib, been observed in vitro, but this BTK inhibitor has also been established as a radio- and chemosensitizer.	ibrutinib	20-29	Bruton tyrosine kinase	Homo sapiens	245-248	
35456016-8	2022	Nevertheless, while ibrutinib failed as a monotherapy, it might become an interesting part of a multidrug regime: not only has a synergism between ibrutinib and other compounds, such as trametinib or dactolisib, been observed in vitro, but this BTK inhibitor has also been established as a radio- and chemosensitizer.	ibrutinib	147-156	Bruton tyrosine kinase	Homo sapiens	245-248